Aclipse Therapeutics Awarded AUD 1 Million Grant from FightMND

Aclipse Therapeutics Selected to Present M102 ALS Clinical Development Program at Prestigious ALS and Motor Neurone Disease Symposia

KING OF PRUSSIA, Penn.–(BUSINESS WIRE)–Aclipse Therapeutics LLC (“Aclipse” or “the Company”) today announced that its M102 drug development program has

November 10, 2024

Aclipse Therapeutics Expands Drug Development Pipeline

Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to

September 14, 2023

Aclipse Therapeutics Announces Publication in Nature Reviews Drug Discovery of an Amyotrophic Lateral Sclerosis Review including M102, a First Targeted Therapy for Sporadic ALS

Radnor, PA, USA – January 2, 2023 – Aclipse Therapeutics, and its subsidiary Aclipse One, Inc (“Aclipse” or “the Company”),

January 2, 2023

Aclipse Therapeutics Announces Issuance of Composition-of-Matter Patent for M102, a First Targeted Therapy for Sporadic ALS

Radnor, PA, USA – November 10, 2022 – Aclipse Therapeutics, and its subsidiary Aclipse One, Inc (“Aclipse” or “the Company”),

November 10, 2022

September 29, 2020

Aclipse Therapeutics was awarded an AUD 1 million (approximately US $720,000) drug development research grant from FightMND, the largest independent funder of ALS research in Australia. The grant will support the translational development of M102, a drug candidate for the treatment of ALS. M102 showed promise to stop and reverse ALS disease progression, as evidenced by data in preclinical models. Currently, there is no cure for ALS and no effective treatments to halt or reverse the progression of this devastating disease.

Learn More